Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

JTZ-951, a HIF-PH inhibitor, shows positive results for treating renal anemia

Jan. 10, 2018

Global Blood Therapeutics' voxelotor given breakthrough therapy designation for sickle cell disease

Jan. 10, 2018

Baxter buys two hemostasis products from Mallinckrodt

Jan. 10, 2018

Enrollment begins in phase II/III program for Catalyst Biosciences' marzeptacog alfa

Jan. 5, 2018

FDA grants breakthrough therapy designation to Promacta for first-line use in severe aplastic anemia

Jan. 4, 2018

Portola Pharmaceuticals provides update on BLA for AndexXa

Dec. 27, 2017

Ironwood Pharmaceuticals begins phase II study of IW-1701 in sickle cell disease

Dec. 22, 2017

First patient treated in phase I study of Achillion's ACH-5228

Dec. 22, 2017

Ticagrelor well tolerated in phase II pediatric sickle cell disease trial

Dec. 21, 2017

BioMarin initiates first phase III study of valoctocogene roxaparvovec for severe hemophilia A

Dec. 20, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 30, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Regulatory actions for July 27, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Alfasigma,...